C07D473/04

PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE
20170326148 · 2017-11-16 ·

The present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in reducing uric acid level, preventing or reducing inflammations, and preventing or treating uratic or gouty diseases. In particular, the present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in the manufacture of a medicament for the treatment or prevention of hyperuricemia, gout, gouty inflammations, pain and uric acid nephropathy.

##STR00001##

R.sub.1 represents hydrogen, C.sub.1-4alkyl or the like. R.sub.2 represents C.sub.1-10alkyl or the like. R.sub.3 represents halogen or the like.

PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE
20170326148 · 2017-11-16 ·

The present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in reducing uric acid level, preventing or reducing inflammations, and preventing or treating uratic or gouty diseases. In particular, the present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in the manufacture of a medicament for the treatment or prevention of hyperuricemia, gout, gouty inflammations, pain and uric acid nephropathy.

##STR00001##

R.sub.1 represents hydrogen, C.sub.1-4alkyl or the like. R.sub.2 represents C.sub.1-10alkyl or the like. R.sub.3 represents halogen or the like.

Substituted Xanthines and Methods of Use Thereof
20170305910 · 2017-10-26 ·

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

Substituted Xanthines and Methods of Use Thereof
20170305910 · 2017-10-26 ·

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

Dual selective PI3 delta and gamma kinase inhibitors

The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.

Dual selective PI3 delta and gamma kinase inhibitors

The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.

Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
09765020 · 2017-09-19 · ·

The invention relates to the compounds of ##STR00001##
related compounds, or pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.

Small molecules against cereblon to enhance effector t cell function

Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.

Substituted xanthines and methods of use thereof

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

Substituted xanthines and methods of use thereof

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.